Moderna Shares Plunge 11% as Biotech Sector Faces Broad Sell-Off

Key Facts

In a move reflecting a sudden shift in risk appetite for growth stocks, the biotechnology sector experienced a broad sell-off that led to sharp losses for major players. Moderna shares dropped 11%, leading the declines in a sector grappling with intense selling pressure. Additionally, shares of ImmunityBio and Sarepta Therapeutics tumbled by 8% each during midday Friday trading, signaling a general weakening of investor confidence across the industry.

This significant decline appears to be a market correction or profit-taking following a massive rally in the biotech sector throughout 2026. Looking at peer performance, industry giants such as Amgen and Gilead Sciences have faced similar pressures recently, as market data indicates investors are re-evaluating high valuations amid ongoing bond yield volatility. According to analyst reports, the absence of immediate positive catalysts has contributed to the accelerated exit from these positions.

Regarding the outlook, traders are monitoring technical support levels for the sector after key levels were breached during today's session. With authoritative price data unavailable for this specific close, the forward-looking sentiment remains cautious pending stabilization in fund flows. On the economic front, the market is awaiting the U.S. Balance of Trade data on July 7, 2026, which may provide further signals on macroeconomic strength and its impact on growth sectors.